Catinazzo Thomas sold $350K of RLAY
Catinazzo Thomas (Chief Financial Officer) sold 17,717 shares of Relay Therapeutics, Inc. (RLAY) at $19.74 ($0.35M total) on 2026-08-14 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure provides transparency on insider activity but does not introduce new operational, financial, or regulatory information about Relay Therapeutics.
Market read
A CFO open-market sale under a 10b5-1 plan is typically a low-signal event for valuation, with limited expected impact on trading.
What to watch
Traders may overreact to insider selling; the key differentiator here is the pre-arranged 10b5-1 structure, which reduces interpretive value.
Background
The article is a SEC Form 4 insider transaction report for Relay Therapeutics, Inc.
Ticker impact
Relay Therapeutics CFO Thomas Catinazzo sold 17,717 shares in an open-market transaction under a 10b5-1 plan, worth about $349.7K.
Likely limited, with any impact confined to short-term sentiment around insider selling.
The filing is a Form 4 insider transaction with a stated 10b5-1 pre-arranged plan; it does not include new company performance, guidance, or regulatory/clinical developments.
Market effects
Minimal; insider-sale disclosures rarely reset sector expectations without accompanying company-specific news.
None indicated.
None indicated.
Counterpoint
Because the sale is under a 10b5-1 plan, it may not signal bearish information; it can be consistent with scheduled liquidity needs.
Key entities
- issuerRelay Therapeutics, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderThomas Catinazzo
Chief Financial Officer who sold shares under a 10b5-1 plan.